BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 15510616)

  • 1. Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma.
    Lüftner D; Genvresse I; Geppert R; Kaufmann O; Dietel M; Possinger K
    Anticancer Res; 2004; 24(5B):3233-7. PubMed ID: 15510616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
    Dorfman DM; Shahsafaei A
    Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu expression in Paget disease of the vulva and the female breast.
    Brummer O; Stegner HE; Böhmer G; Kühnle H; Petry KU
    Gynecol Oncol; 2004 Nov; 95(2):336-40. PubMed ID: 15491754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
    Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
    Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paraneoplastic lymphadenopathy].
    Melikian AL; Nikitin EA; Kaplanskaia IB; Frank GA
    Ter Arkh; 2007; 79(8):44-52. PubMed ID: 17926471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical determination of HER-2/neu in malignant melanoma.
    Potti A; Hille R; Koch M
    Anticancer Res; 2003; 23(5A):4067-9. PubMed ID: 14666720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
    Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
    Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
    Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
    Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
    Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
    Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Presence of bcl-2 and p53 proteins in patients with non-Hodgkin's lymphoma at Zadar General Hospital].
    Skunca Z; Gverić-Krecak V; Dominis M; Planinc-Peraica A; Jaksić B
    Acta Med Croatica; 2004; 58(3):183-6. PubMed ID: 15503680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of HER-2/neu in testicular tumors.
    Mandoky L; Geczi L; Bodrogi I; Toth J; Bak M
    Anticancer Res; 2003; 23(4):3447-51. PubMed ID: 12926088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.
    Osman I; Mikhail M; Shuch B; Clute M; Cheli CD; Ghani F; Thiel RP; Taneja SS
    J Urol; 2005 Dec; 174(6):2174-7. PubMed ID: 16280758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
    Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of HER-2/neu expression in Hodgkin and non-Hodgkin lymphoma.
    Bairey O; Pazgal I; Okon E; Shaklai M; Morgenshtern S
    Arch Pathol Lab Med; 2002 May; 126(5):574-6. PubMed ID: 11958663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycosis fungoides associated with B-cell malignancies.
    Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
    Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma.
    Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M
    Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomorphologic characteristics of non-Hodgkin's lymphoma.
    Bizjak-Schwarzbartl M
    Acta Cytol; 1988; 32(2):216-20. PubMed ID: 2450436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cigarette smoking and risk of non-Hodgkin's lymphoma--a population-based case-control study.
    Schöllkopf C; Smedby KE; Hjalgrim H; Rostgaard K; Gadeberg O; Roos G; Porwit-Macdonald A; Glimelius B; Adami HO; Melbye M
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1791-6. PubMed ID: 16030118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.